

1 Genomic epidemiology of the rotavirus G2P[4] strains in coastal Kenya pre- and post-  
2 rotavirus vaccine introduction, 2012 – 2018

3

4 Timothy O. Makori <sup>1,2</sup>, Joel L. Bargul <sup>2,3</sup>, Arnold W. Lambisia <sup>1</sup>, Mike J. Mwangi <sup>1</sup>, Nickson  
5 Murunga <sup>1</sup>, Zaydah R. de Laurent <sup>1</sup>, Clement S. Lewa <sup>1</sup>, Martin Mutunga <sup>1</sup>, Paul Kellam<sup>4, 5</sup>,  
6 Matthew Cotten <sup>6,7</sup>, D. James Nokes <sup>1,8</sup>, My Phan<sup>6, 7,\*</sup>, and Charles N. Agoti <sup>1, 9,\*</sup>

7

8 Affiliations:

- 9 1. Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme,  
10 off Hospital Road, Kilifi 80108, Kenya; tmakori@kemri-wellcome.org (T.O.M.);  
11 ALambisia@kemri-wellcome.org (A.W.L.); jmwanga@kemri-wellcome.org  
12 (M.J.M.); nmurunga@kemri-wellcome.org (N.M.); zdelaurent@gmail.com  
13 (Z.R.d.L.); CLewa@kemri-wellcome.org (C.L.); MMutunga@kemri-wellcome.org  
14 (M.M.); jnokes@kemri-wellcome.org (D.J.N.); cnyaigoti@kemri-wellcome.org  
15 (C.N.A.).
- 16 2. Department of Biochemistry, Jomo Kenyatta University of Agriculture and  
17 Technology, Juja 62000-00200, Kenya; Jbargul@jkuat.ac.ke (J.L.B).
- 18 3. International Centre of Insect Physiology and Ecology, Animal Health Theme, P.O.  
19 Box 30772-00100, Nairobi, Kenya; jbargul@icipe.org (J.L.B).
- 20 4. Department of Infectious Diseases, Faculty of Medicine, Imperial College London,  
21 London, UK; p.kellam@imperial.ac.uk (P.K)
- 22 5. Kymab Ltd, The Bennet Building (B930), Babraham Research Campus, Cambridge,  
23 UK
- 24 6. Medical Research Centre (MRC)/ Uganda Virus Research Institute, Entebbe, Uganda
- 25 7. MRC-University of Glasgow, Centre for Virus Research Glasgow, United Kingdom;  
26 Matthew.Cotten@lshtm.ac.uk (M.C.); My.Phan@lshtm.ac.uk (MP).
- 27 8. School of Life Sciences and Zeeman Institute (SBIDER), The University of Warwick,  
28 Coventry CV4 7AL, UK
- 29 9. School of Health and Human Sciences, Pwani University, Kilifi 80108, Kenya

30

31 Keywords:

32 Rotavirus group A, G2P[4], Coastal Kenya

33

34

35 ABSTRACT

36 The introduction of rotavirus vaccines into the national immunization programme in many  
37 countries has led to a decline of childhood diarrhoea disease burden. Coincidentally, the  
38 incidence of some rotavirus group A (RVA) genotypes, has increased, which may result from  
39 non-vaccine-type replacement. Here we investigate the evolutionary genomics of rotavirus  
40 G2P[4] which has shown an increase in countries that introduced the monovalent Rotarix®  
41 vaccine. We examined the 63 RVA G2P[4] strains sampled from children (aged below 13  
42 years) admitted to Kilifi County Hospital, Coastal Kenya, pre- (2012 to June 2014) and post-  
43 (July 2014-2018) rotavirus vaccine introduction. All the 63 genome sequences showed a  
44 typical DS-1 like genome constellation G2-P[4]-I2-R2-C2-M2-A2-N2-T2-E2-H2. G2 sub-  
45 lineage IVa-3 strains predominated in the pre-vaccine era co-circulating with low numbers of  
46 G2 sub-lineage IVa-1 strains, whereas sub-lineage IVa-3 strains dominated the post-vaccine  
47 period. In addition, in the pre-vaccine period, P[4] sub-lineage IVa strains co-circulated with  
48 low numbers of P[4] lineage II strains, but P[4] sub-lineage IVa strains predominated in the  
49 post-vaccine period. On the global phylogeny, the Kenyan pre- and post-vaccine G2P[4]  
50 strains clustered separately, suggesting that different virus populations circulated in the two  
51 periods. However, the strains from both periods exhibited conserved amino acid changes in  
52 the known antigenic epitopes, suggesting that replacement of the predominant G2P[4] cluster  
53 was unlikely a result of immune escape. Our findings demonstrate that the pre- and post-  
54 vaccine G2P[4] strains circulating in Kilifi, coastal Kenya, differed genetically, but likely  
55 were antigenically similar. This information informs the discussion on the consequences of  
56 rotavirus vaccination on rotavirus diversity.

57

58

59 INTRODUCTION

60 In 2009, the World Health Organization (WHO) recommended inclusion of rotavirus  
61 vaccines into the national immunization programmes (NIPs) globally [1]. Kenya introduced  
62 the WHO pre-qualified Rotarix® RVA (rotavirus group A) vaccine into its NIP in July 2014  
63 [2]. With the increasing uptake of rotavirus vaccines globally, there has been a significant  
64 reduction in RVA-associated disease burden, but this virus still caused about 128,500 deaths  
65 in 2016 alone [3,4], with the majority of cases occurring in low-income countries [5]. In  
66 Kenya, post-vaccine introduction impact studies have reported significant reduction of  
67 rotavirus-associated diarrhoea hospitalization in children under five years, a vaccine  
68 effectiveness of ~64% [6], and a significant increase in the positivity rate of Rotarix®  
69 heterotypic genotypes such as G2P[4] and G3P[8] [7,8]. Similar findings were observed in  
70 other countries that introduced the Rotarix® vaccine in their NIPs [9–18]

71 Whole genome analysis of RVA can reveal the transmission and evolutionary history of  
72 circulating strains, including emerging mutations, and the origins and genetic diversity of the  
73 strains circulating in a particular region [19]. The rotavirus G2P[4] genotype is known to  
74 possess a DS-1 like genomic constellation (G2-P[4]-I2-R2-C2-M2-A2-N2-T2-E2-H2) [20].  
75 G2P[4] strains are believed to have undergone genetic evolution in a stepwise pattern [21].  
76 This is from lineage I to IVa in the NSP5, NSP1, VP2, VP4, and VP7 genome segments, and  
77 from lineage I to V in the VP1, VP3, VP6, NSP2, NSP3, and NSP4 genome segments, with  
78 some of the strains undergoing intragenotype reassortments in the VP7, VP3, and NSP4  
79 genes after 2004 giving rise to emergent lineages of V in the VP7 segment, lineages VI and  
80 VII in the VP3 gene, and VI, VII, VIII, IX and X lineages in the NSP4 gene [21–23]. The  
81 G2P[4] lineages circulating in Kenya are unknown.

82 Characterization of South African G2P[4] strains, through comparison of strains  
83 occurring during pre-and post-introduction of Rotarix® vaccine, revealed sub-lineage shifts  
84 from G2 sub-lineage IVa-1 to G2 IVa-3, and P[4] sub-lineage IVa to P[4] IVb, and these  
85 shifts in genetic evolution were attributed to arise due to natural fluctuations and not as a  
86 result of vaccine pressure [24]. Similarly, G2P[4] whole genome analysis in Ghana [22],  
87 Australia [25,26], South Korea [11], Bangladesh [27], and Brazil [28] showed that  
88 implementation of Rotarix® vaccination does not influence genetic diversity of the  
89 circulating G2P[4] strains and common amino acid replacements in the VP7 antigenic  
90 epitopes including A87T, D96N, S213D were reported, irrespective of the vaccination period.

91 The main goal of this study was to conduct whole genome analysis of the G2P[4]  
92 genotypes circulating in Kilifi County, Kenya, to determine whether introduction of Rotarix®  
93 vaccine in Kenya's NIP impacts on the genetic diversity of the circulating G2P[4] viral  
94 populations. Data from this study were compared with contemporaneous global RVA strains  
95 to establish the phylogenetic context and potential origin of the Kenya's pre- and post-  
96 vaccination rotavirus G2P[4] strains.

## 97 MATERIALS AND METHODS

### 98 *Ethical approval*

99 We collected samples from children to screen for and determine the genetic diversity of  
100 rotavirus group A (RVA) viral populations. The study was conducted with strict adherence to  
101 the study protocols approved by the Scientific and Ethics Review Unit (REF: #3049 and  
102 #2861) at the Kenya Medical Research Institute, KEMRI, Nairobi, Kenya. Parents and  
103 guardians of the eligible children were provided with sufficient information about the  
104 research study to allow each individual to make informed and independent decisions for their  
105 children to be enrolled in the study. Sample collection proceeded after obtaining written  
106 informed consent from the parents and guardians.

### 107 *Study participants*

108 The study was based at Kilifi County Hospital (KCH), a referral health facility that mainly  
109 serves the people of Kilifi County located in the North Coast of Kenya [29]. Stool samples  
110 were obtained from children, aged below 13 years, who presented with diarrhoea as one of  
111 the illness symptoms and were admitted at KCH [6,30]. Diarrhoea was defined as passing of  
112 watery stool at least three times in the last 24 hours.

113 The stool samples were screened to detect RVA by using ELISA kit (ProSPect™; Oxoid,  
114 Basingstoke UK). All the RVA positive samples were initially genotyped by partial segment  
115 sequencing approach [7]. VP7 and VP4 genes were sequenced, and G and P genotypes  
116 inferred using the Virus Pathogen Resource (VIPR) tool for RVA [31]. Those classified as  
117 G2P[4] based on the outer capsid proteins were selected for this study (Fig. 1) [7].

### 118 *RNA extraction and processing*

119 The samples collected in the pre-vaccine period (January 2012 – June 2014) were  
120 sequenced using agnostic whole genome sequencing method [32], while the post-vaccine

121 samples (July 2014 – December 2018) were sequenced using an amplicon-based whole  
122 genome sequencing approach [33,34].

123 Processing of pre-vaccine samples was done by centrifugation of 110 µL of stool  
124 suspension in PBS (phosphate buffered saline) for 10 minutes at 10,000 × g. Next, 2 U/µl of  
125 TURBO DNase (#AM2238; Life Technologies, Carlsbad, USA) were added to degrade non-  
126 encapsulated DNA. Nucleic acid extraction was performed according to the Boom method  
127 [35]. First strand cDNA was synthesized using the SuperScript III Reverse Transcriptase Kit  
128 (#18064014; Life Technologies, Carlsbad, USA) with non-ribosomal random hexamer  
129 primers [36]. Second strand cDNA was synthesized using 5U of Klenow fragment 3' – 5'  
130 exo- (#M0212S; New England Biolabs, Ipswich, USA).

131 Processing of post-vaccine introduction samples was done by subjecting 200 mg of stool  
132 specimens to bead beating [37], followed by nucleic acid extraction using the QIAamp Fast  
133 DNA Stool Mini kit (#51604; Qiagen, Manchester, UK) following the manufacturer's  
134 instructions. Reverse Transcription-PCR (RT-PCR) was performed using the SuperScript IV  
135 One-Step RT-PCR System (#2594025, Thermo Fisher Scientific, Waltham, USA) following  
136 the manufacturer's instructions. The published primers used in our study to conduct RT-PCR  
137 assays were adopted from earlier studies (Table S1) [33,34]. The PCR conditions for the non-  
138 structural gene segments (NSP1, NSP2, NSP3, NSP4, and NSP5) consisted of 40 cycles of  
139 thermocycling (30 seconds at 90°C, one minute at 55°C, and four minutes at 68°C), whereas  
140 amplification of structural gene segments (VP1, VP2, VP3, VP4, VP6, and VP7) included 40  
141 cycles of thermocycling (90°C for 30 seconds, 61°C for one minute and 68°C for six  
142 minutes), and included a final extension at 72°C for four minutes. PCR amplicons were  
143 resolved under a 2% agarose gel stained with RedSafe (iNtRON Biotechnology, Inc) for  
144 visualization of DNA bands. PCR products were purified using Exonuclease I (#EN0581;  
145 Thermo Fisher Scientific, Waltham, USA) as described by the manufacturer and pooled for  
146 each sample.

#### 147 *Next generation sequencing*

148 Preparation of standard Illumina libraries for pre-vaccine samples was performed  
149 according to the published protocol [32]. Briefly, the double-stranded cDNA for each sample  
150 was sheared to obtain 400 – 500 nucleotide fragments. Each sample was then indexed  
151 separately to unique adapters and multiplexed at 95 samples and then sequenced on a HiSeq  
152 platform to generate about 1.5 million 250bp paired end reads per sample.

153 For the post-vaccine samples was done by purifying the pooled amplicons for each sample  
154 using the Agencourt AMPure XP Kit (#A63881; Beckman Coulter, USA) as described by the  
155 manufacturer. Library preparation was performed using the Illumina DNA flex (#20025519,  
156 Illumina, San Diego, USA) as per the manufacturer’s specifications. Briefly, bead-linked  
157 transposomes were used to tagment the DNA, followed by addition of adapters to the DNA  
158 fragments using a limited PCR program. The adapter-linked DNA was cleaned using the  
159 tagment wash buffer. After that, the purified tagmented DNA was amplified via a limited-  
160 cycle PCR program that adds the i7, i5 adapters and sequences required for cluster generation  
161 during sequencing. Next, the amplified libraries were purified using a double-sided bead  
162 purification method. Subsequently, each DNA library was quantitated, and correct insert sizes  
163 confirmed on an Agilent 2100 Bioanalyzer using the Agilent high sensitivity DNA kit  
164 (#5067; Agilent, Santa Clara, USA). The DNA libraries were quantified on the Qubit  
165 fluorimeter 2.0 using the Qubit dsDNA HS Assay kit (#Q32851, Life Technologies, Thermo  
166 Fisher Scientific, Waltham, USA), normalized, and pooled at equimolar concentrations.  
167 Pooled DNA libraries were denatured and sequenced on the Illumina MiSeq platform  
168 (Illumina, San Diego, USA) to generate 150 paired end reads.

#### 169 *Genome assembly*

170 Quality trimming of Illumina FASTQ reads was done using Trimmomatic (Phred score  
171 >30) with the following flags “ILLUMINACLIP: adapters\_file: 2:30:10 LEADING:3  
172 TRAILING:3 SLIDINGWINDOW: 4:15 MINLEN:36” to remove adapters and low-quality  
173 bases [38]. De-Novo assembly of the quality trimmed reads was done using Spades with the  
174 following flags “-k 99,127 --careful” [39]. For the pre-vaccine sequences, RVA-specific  
175 contigs were identified using USEARCH [40] and a SLIM algorithm [41]. Partial and  
176 overlapping contigs were joined using Sequencher [42] to obtain full-length sequences. For  
177 the post-vaccine sequences, Quast was used to check the quality of the contigs [43]. Next,  
178 artemis was employed to determine the ORFs of each RVA segment [44]. Then, genotyping  
179 of the assembled pre- and post-vaccine sequences was done using the Virus Pathogen  
180 Resource tool for RVA [31]. The nucleotide sequences generated in this study have been  
181 deposited into GenBank under accession numbers MZ093788 to MZ097268 and OP677569  
182 to OP677754 (Table S2).

#### 183 *Global sequences collection and processing*

184 All available G2P[4] sequences irrespective of the sequence length and their  
185 corresponding metadata, including year of collection and location were downloaded from the  
186 Virus Pathogen Resource of RVA [31]. Records missing metadata were manually searched

187 and any information, including location and collection year, that could be found in the  
188 primary publications was included in the respective sequence data. The sequences were  
189 subset to obtain datasets of each genome segment. The datasets of all the genome segments  
190 were filtered to only include samples with all the 11 segments. For all the 11 segments, more  
191 than 80 % of the coding sequence (CDS) region was considered for analysis. Overall, 350  
192 global sequences for each segment met the inclusion criteria for phylogenetic analyses (Table  
193 S2).

#### 194 *Phylogenetic analysis*

195 The global dataset was combined with the sequences of this study for each genome  
196 segment and aligned using MAFFT (v7.487) with the command “mafft --auto --reorder --  
197 preservecase input\_file.fasta > output\_file.fasta” [45]. Maximum likelihood phylogenetic  
198 trees were reconstructed using IQTREE2 (v2.1.3) [46] using the best model selection [47]  
199 and 1000 bootstrap replication settings [48]. The ML trees were linked to the respective  
200 metadata in R v4.1.0 and the “ggTree” R package used to plot and visualize the trees [45].  
201 For lineage designation, sequences of previously described lineages for each segment [21–23]  
202 were utilized as the references (Table S2).

#### 203 *Statistical analyses*

204 All statistical analyses were carried out using Stata v13.1 [49]. Chi-square test was used to  
205 compare among groups, with  $P < 0.05$  indicating statistical significance.

## 206 RESULTS

### 207 *Baseline characteristics of the study participants*

208 Peaks of rotavirus A (RVA) infections coincided with cases of diarrhoea during the study  
209 period between May and September (Fig. 1). However, sample collection was majorly  
210 disrupted in 2016 and 2017 by strikes of health care providers (Fig. 1) [6]. One huge peak of  
211 G2P[4] infections was observed between June and November 2016 (post-vaccine) and a  
212 small one documented between May and September 2012 (pre-vaccine) (Fig. 1).

213 No significant difference was reported in age, age groups, gender, and vaccination status  
214 between the cases infected with G2P[4] genotypes and the non-G2P[4] genotypes ( $P > 0.05$ )  
215 (Table 1). G2P[4] genotypes were detected in 87 samples (20.3%), of which 63 (14.7%) were  
216 successfully full-genome sequenced (Table 1). Of the sequenced samples, 13 (20.6%) were  
217 from children who received two doses of the Rotarix® vaccine (Table 1).

## 218 *Genome constellations*

219 To determine the genetic diversity in the Kilifi G2P[4] strains and their genetic relatedness  
220 with global strains, near full-genome sequences (>80% genome coverage) of 63 Kilifi  
221 samples were sequenced from the pre- (n=33) and the post- (n=30) vaccine periods (Table  
222 S2). Using the Virus Pathogen Resource (VIPR) for RVA genotype determination [31], all  
223 the 63 sequences were classified as G2-P[4]-I2-R2-C2-M1-A2-N2-T2-E2-H1 genotype (DS-  
224 1-like typical genome constellation) as shown in Table S3.

## 225 *Phylogenetic and sequence analysis*

226 To gain insights into the genetic diversity of the study G2P[4] strains in the global context,  
227 genetic distance-resolved phylogenetic trees were constructed for all the 11 gene segments  
228 (Fig. 2 & Fig. S1). Sequence identity matrices of the study G2P[4] strains exhibited high  
229 nucleotide sequence similarities (93 – 100%) in the NSP1, NSP2, NSP3, NSP5, VP1, VP2,  
230 VP4, VP6, and VP7 genome segments, and low to high nucleotide sequence similarity (85 –  
231 100%) in the VP3 and NSP4 genes (Table 2).

## 232 *Analysis of the VP7 gene*

233 The VP7 gene is highly variable and encodes the humoral immune response glycoprotein  
234 [50]. The VP7 genetic distance-resolved phylogenetic tree showed that the Kilifi sequences  
235 formed three clusters: a monophyletic cluster, a minor monophyletic cluster, and a singleton  
236 (Fig. 2). Within the major cluster, the Kilifi strains separated by vaccination period, with one  
237 subcluster consisting of strains circulating two years after Rotarix® vaccine introduction and  
238 were interspersed with three strains isolated from children admitted to Kenyatta National  
239 Hospital (KNH), Kenya in 2017 (Fig. 2). These sequences shared two non-synonymous  
240 amino acid substitutions (S72G, S75L) with respect to the pre-vaccine strains (Table S4). The  
241 second subcluster mainly consisted of strains circulating in the pre-vaccine period and two  
242 strains that circulated in July 2014, i.e., early post-vaccine period (Fig. 2). The sequences in  
243 the minor monophyletic cluster consisted of five Kilifi strains collected in 2012, while the  
244 singleton Kilifi strain (KLF1033/2018) clustered with three strains detected in Mozambique  
245 in 2013 (Fig. 2).

246 With regards to the VP7 lineages, the Kilifi G2 strains were classified into lineage IV and  
247 further classified into sub-lineage IVa-1 and IVa-3 (Fig. 2). In 2012, sub-lineages IVa-1 and  
248 IVa-3 sequences co-circulated in Kilifi, while in the global context sub-lineages IVa-1, IVa-3  
249 and IV non-a co-circulated (Fig. 3A). However, IVa-1 strains in Kilifi were replaced with  
250 sub-lineage IVa-3 strains in 2013 that dominated until 2018 (Fig. 3A), unlike in the global



251 context where sub-lineages IVa-1, IVa-3 and V co-circulated in 2013, sub-lineage IVa-1  
252 predominantly circulated in 2014, IVa-1 and V co-circulated in 2015, and IVa-3 re-emerged  
253 in 2016 replacing lineage V and co-circulated with sub-lineage IVa-1 until 2018 (Fig. 3A).  
254 No lineage shift was observed pre- and post-vaccine introduction.

#### 255 *Analysis of the VP4 gene*

256 The VP4 gene is highly variable and encodes a highly immunogenic protease sensitive  
257 protein involved in receptor binding and cell penetration [50]. In the VP4 phylogenetic tree,  
258 the P[4] Kilifi sequences formed clusters ( $n > 2$ ) mainly based on the vaccination period  
259 separated from global sequences (Fig. 2). However, two Kilifi sequences formed singletons,  
260 with the KLF1033/2018 strain clustering with a sequence isolated from a child admitted to  
261 KNH, while the KLF0616/2012 strain was interspersed with sequences from Mozambique  
262 (Fig. 2). A major cluster of Kilifi sequences further sub-clustered based on the vaccination  
263 period, with the post-vaccine sequences interspersing with Kenyan sequences isolated from  
264 children admitted to KNH (Fig. 2). In addition, Kilifi strains collected in 2014 and some 2012  
265 strains formed two distinct clades, clustering separately from global sequences (Fig. 2).

266 During the study period, G2 lineages II and IVa strains circulated in Kilifi, with lineages II  
267 and IV co-circulating in 2012, consistent with the global context (Fig. 3B). From 2013 to  
268 2018, sub-lineage IVa predominantly circulated in Kilifi similar the global context (Fig. 3B).  
269 However, in the global context, few lineage II strains co-circulated with IVa strains in 2017  
270 (Fig. 3B). No lineage shift was observed pre- and post-vaccine introduction (Fig 2).

#### 271 *Analysis of the backbone genome segments*

272 The backbone genome segments of the Kilifi G2P[4] strains (VP6, VP1-VP3, and NSP1-  
273 NSP5) formed up to four clusters on the global phylogenetic trees (Fig.S1). In the VP6, VP1,  
274 VP2, VP3, NSP1, and NSP2 genes, majority of the Kilifi sequences formed one major cluster  
275 which further separated into two sub-clusters of only pre- and post-vaccine sequences (Fig.  
276 S1). The post-vaccine strains in these genes clustered closely with 2017 sequences from  
277 KNH, Kenya (Fig.S1). In addition, the Kilifi 2014 sequences in the VP6, VP3, NSP1, and  
278 NSP2 segments exhibited a different clustering pattern of a further minor sub-cluster  
279 irrespective of the vaccination period, consistent with the VP4 gene (Fig. S1). Four post-  
280 vaccine sequences were interspersed with the pre-vaccine sequences in the NSP4 gene and a  
281 singleton of post-vaccine sequence clustered with pre-vaccine sequences in the NSP3 gene  
282 (Fig. S1). The NSP5 post-vaccine sequences formed one cluster, while the pre-vaccine

283 sequences exhibited a different clustering pattern consisting of three distinct clusters ( $n \geq 2$ )  
284 and three singletons (KLF0601/2012 was interspersed with a sequence from KNH,  
285 KLF1066/2014 and KLF0722/2014) (Fig. S1). A minor cluster consisting of five Kilifi pre-  
286 vaccine strains (KLF0550/2012, KLF0551/2012, KLF0553/2012, KLF0558/2012, and  
287 KLF1064/2012) separate from global sequences was observed in the VP1, VP2, VP3, NSP2,  
288 NSP4, and NSP5 genes; however, interspersed with sequences that circulated between 2012  
289 and 2017 in Japan, Hungary, Australia, and Belgium in the NSP3 gene and further formed  
290 two sub-clades in the VP6 gene (Fig. S1). In addition, a minor cluster of Kilifi pre-vaccine  
291 sequences (KLF0640/2013, KLF0673/2013, and KLF0657/2013) interspersed with sequences  
292 from Malawi was observed in the VP3 gene, indicating possible importation of these strains  
293 (Fig. S1). Besides, a singleton of a post-vaccine sequence (KLF1033/2018) was interspersed  
294 with sequences from Mozambique that circulated in 2013 across all the backbone genes (Fig.  
295 S1). For the NSP5 gene, three other singletons were observed: KLF0601/2012 interspersed  
296 with a sequence from KNH, KLF1066/2014 and KLF0722/2014 each separate from global  
297 sequences (Fig. S1). No lineage shifts were reported in the backbone genome segments (Fig.  
298 S1).

#### 299 *Amino acid changes in the VP7 glycoprotein (G) and VP4 Protease sensitive (P) proteins*

300 The pattern of amino acid (aa) substitutions in the G and P proteins was analysed in  
301 relation to the ancestral DS-1 sequence. The VP7 gene contains 7-1 (7-1a and 7-1b) and 7-2  
302 antigenic epitopes, which affect the ability of antibodies to neutralize virus infectivity and  
303 reduce vaccine effectiveness [51]. The Kilifi strains exhibited 17 aa changes relative to the  
304 DS-1 VP7 ancestral sequence (Table S4). All the Kilifi strains had three aa mutations (D96N,  
305 N125T, and V129M) in the 7-1a antigenic epitope with respect to the DS-1 ancestral strain  
306 (Fig. 4 & Table S4). Furthermore, except for the 2014 sequences, the Kilifi sequences  
307 exhibited an A87T aa mutation in the 7-1a epitope (Table S4). Compared to the DS-1  
308 sequence, the Kilifi sub-lineage IVa-1 strains exhibited the N242 aa mutation, whereas sub-  
309 lineage IVa-3 strains harboured the N213D aa mutation; both in the 7-1b epitope. (Table S4).  
310 Besides, the I44M aa change was observed in the T lymphocyte epitope (40 – 52) of all the  
311 Kilifi strains (Table S4).

312 The VP4 surface protein is cleaved into the VP8\* and the VP5\* domains containing the 8-  
313 1 to 8-4 and 5-1 to 5-5 antigenic epitopes [52]. Analysis of the VP4 aa mutations revealed  
314 that the Kilifi strains differed only at three positions; Q114P or L114P and N133S in the 8-3

315 epitope and N89D in the 8-4 epitope, relative to the DS-1 prototype sequence (Fig 4 & Table  
316 S5).

## 317 DISCUSSION

318 We investigated the evolutionary dynamics of G2P[4] strains sampled from children  
319 admitted to Kilifi County Hospital, Coastal Kenya between 2012 and 2018. All the recovered  
320 genomes showed a typical DS-1 like constellation consistent with findings from several  
321 countries using the Rotarix® vaccine in their NIPs [21,22,24,53].

322 Separate clusters of pre- and post-vaccine sequences were observed in the VP1-VP4, VP6,  
323 VP7, NSP1, NSP2, and NSP5 segments. However, the strains sampled in July 2014 (early  
324 post-vaccine period) clustered with pre-vaccine strains across all the 11 gene segments in our  
325 study possibly because the vaccine coverage was low and thus had no impact yet on the  
326 circulating genotypes and lineages. Unique clusters of either G2P[4] or G1[P8] strains  
327 separated by RVA vaccine period have been reported in South Africa [24], Rwanda [54],  
328 Australia and Belgium [55], which were interpreting as reflecting natural genetic fluctuations  
329 rather than vaccine induced evolution. However, the study NSP4 and NSP3 genes exhibited  
330 some clusters of mixed pre- and post-vaccine sequences, indicating that in some strains the  
331 pre-vaccine may have reassorted with post-vaccine introduction strains as similarly suspected  
332 in Mozambique, albeit in G1P[8] [56].

333 Phylogenetic analyses indicated that the diversity of the Kilifi G2P[4] strains may have  
334 been locally restricted both in the pre- and post-vaccine periods, since Kilifi sequences  
335 clustered away from global sequences in all the 11 genome segments. In addition, limited  
336 sequence data from Kenya and East Africa may have contributed to this uncertainty about the  
337 regional context of Kilifi diversity. The Kilifi post-vaccine strains only clustered with  
338 Kenyan sequences sampled from children admitted to Kenyatta National Hospital in 2017,  
339 further suggesting locally restricted genetic evolution. However, one sample  
340 (KLF1033/2018) consistently clustered with sequences from Mozambique and some pre-  
341 vaccine strains were interspersed with global strains for the NSP3 segment, suggestive of  
342 limited introduction from other countries. No lineage shift was observed pre- and post-  
343 periods in Kilifi inconsistent with findings in South Africa [24] where RVA vaccine  
344 introduction resulted in lineage shift. Furthermore, few G2 and P[4] lineages were in  
345 circulation within Kilifi compared with the combined global data during the study period.

346 This supported our hypothesis that local drivers were responsible for the diversity within the  
347 Kilifi setting.

348 The Kilifi strains harbored six conserved amino acid (aa) substitutions in the VP7  
349 antigenic epitopes; 7-1a and 7-1b with respect to the ancestral DS-1 G2P[4] strain. Three of  
350 these positions (A87T, D96N, and N213D) are critical for antibody binding and sequence  
351 changes here may lead to escape from host neutralizing antibodies [57]. The I44M aa change  
352 may affect cellular immunity as this region harbors a known T lymphocyte epitope (40-52) of  
353 the VP7 genes. All Kilifi strains had this change that potentially result in loss of recognition  
354 by T cells leading to escape from host immune responses [58,59]. Three aa acid changes were  
355 observed in VP4 antigenic epitopes in 8-4 (N89D) and 8-3 (Q114P or L114P and N133S) in  
356 the Kilifi strains. These have been associated with escape of attachment of the virus to host  
357 neutralizing monoclonal antibodies [60]. These aa substitutions were present in both pre- and  
358 post-vaccine Kilifi strains, suggesting they were not brought about by vaccine use.

359 This study had limitations. First, only sequences sampled from hospitalized children were  
360 analysed, thus may not conclusively reflect diversity that was in circulation in the entire  
361 coastal Kenya population. We only analysed a few genomes across the years. Second, we  
362 only recovered near complete genomes. Only 68% coverage was recovered in the VP4  
363 segment.

364 In conclusion, our study reinforces the significance of genomic sequencing in monitoring  
365 the effect of vaccine pressure on circulating RVA strains in Kenya. The Kilifi strains to a  
366 large extent clustered based on the vaccination period and were separate from the global  
367 strains. Furthermore, conserved amino acid mutations were observed in the VP7 and VP4  
368 antigenic epitopes of the pre- and post-vaccine strains, suggesting that the Rotarix® vaccine  
369 did not have a direct impact on the evolution of the circulating strains.

#### 370 Data availability

371 The epidemiological data is available on the VEC dataverse  
372 (<https://doi.org/10.7910/DVN/P4MRVF>).

#### 373 Funding information

374 This study was funded by the Wellcome Trust (102975, 203077). The authors Timothy  
375 Makori, and Charles Agoti were supported by the Initiative to Develop African Research  
376 Leaders (IDeAL) through the DELTAS Africa Initiative (DEL-15-003). The DELTAS Africa

377 Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s  
378 Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New  
379 Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency)  
380 with funding from the Wellcome Trust (107769/Z/10/Z) and the UK government. The views  
381 expressed in this publication are those of the authors and not necessarily those of AAS,  
382 NEPAD Agency, Wellcome Trust or the UK government.

383

#### 384 Acknowledgement

385 We thank all the study participants for their contribution of study samples, their  
386 parents/guardians, members of the viral epidemiology and control research group  
387 (<http://virec-group.org/>) and colleagues at the KEMRI Wellcome Trust Research Programme  
388 for their useful discussions during the preparation of the manuscript. This paper is published  
389 with the permission of the Director of KEMRI.

390

#### 391 Conflicts of interest

392 The authors declare no conflict of interest

393

394 References

- 395 1. WHO Rotavirus Vaccines. Rotavirus vaccines: WHO position paper - July 2021  
396 [Internet]. 2021 [cited 2022 Aug 2]. Available from:  
397 <https://www.who.int/publications/i/item/WHO-WER9628>
- 398 2. Varghese T, Kang G, Steele AD. Understanding Rotavirus Vaccine Efficacy  
399 and Effectiveness in Countries with High Child Mortality. *Vaccines (Basel)*  
400 [Internet]. 2022 Mar 1 [cited 2022 Aug 2];10(3). Available from:  
401 [/pmc/articles/PMC8948967/](https://pubmed.ncbi.nlm.nih.gov/3948967/)
- 402 3. Tate JE, Burton AH, Boschi-Pinto C, et al. Global, Regional, and National  
403 Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000-2013.  
404 *Clinical Infectious Diseases* [Internet]. 2016 May 1 [cited 2020 Oct  
405 20];62(suppl\_2):S96-105. Available from:  
406 [https://academic.oup.com/cid/article/62/suppl\\_2/S96/2478843](https://academic.oup.com/cid/article/62/suppl_2/S96/2478843)
- 407 4. Troeger C, Khalil IA, Rao PC, et al. Rotavirus Vaccination and the Global  
408 Burden of Rotavirus Diarrhea among Children Younger Than 5 Years. *JAMA*  
409 *Pediatr* [Internet]. 2018 Oct 1 [cited 2020 Oct 20];172(10):958-65. Available  
410 from: <https://jamanetwork.com/>
- 411 5. Troeger C, Blacker BF, Khalil IA, et al. Estimates of the global, regional, and  
412 national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a  
413 systematic analysis for the Global Burden of Disease Study 2016. *Lancet Infect*  
414 *Dis* [Internet]. 2018 Nov 1 [cited 2020 Oct 20];18(11):1211-28. Available from:  
415 [/pmc/articles/PMC6202444/?report=abstract](https://pubmed.ncbi.nlm.nih.gov/3202444/)
- 416 6. Khagayi S, Omoro R, Otieno GP, et al. Effectiveness of Monovalent Rotavirus  
417 Vaccine Against Hospitalization With Acute Rotavirus Gastroenteritis in  
418 Kenyan Children. 2020 May 23 [cited 2020 Oct 26];70(11):2298-305.  
419 Available from: <https://academic.oup.com/cid/article/70/11/2298/5536640>
- 420 7. Mwangi MJ, Owor BE, Ochieng JB, et al. Rotavirus group A genotype  
421 circulation patterns across Kenya before and after nationwide vaccine  
422 introduction, 2010-2018. *BMC Infect Dis* [Internet]. 2020 Jul 13 [cited 2020  
423 Oct 26];20(1):504. Available from:  
424 <https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05230-0>
- 425 8. Gikonyo JN u., Mbatia B, Okanya PW, Obiero GFO, Sang C, Steele D,  
426 Nyangao J. Post-vaccine rotavirus genotype distribution in Nairobi County,  
427 Kenya. *International Journal of Infectious Diseases* [Internet]. 2020 Nov 1 [cited  
428 2022 Jun 12];100:434. Available from: [/pmc/articles/PMC7670220/](https://pubmed.ncbi.nlm.nih.gov/37670220/)
- 429 9. Vizzi E, Piñeros OA, Oropeza MD, et al. Human rotavirus strains circulating in  
430 Venezuela after vaccine introduction: predominance of G2P[4] and reemergence  
431 of G1P[8]. *Virology* [Internet]. 2017 Mar 21 [cited 2022 Aug 2];14(1):1-14.  
432 Available from: [https://virologyj.biomedcentral.com/articles/10.1186/s12985-](https://virologyj.biomedcentral.com/articles/10.1186/s12985-017-0721-9)  
433 [017-0721-9](https://virologyj.biomedcentral.com/articles/10.1186/s12985-017-0721-9)
- 434 10. Roczo-Farkas S, Kirkwood CD, Cowley D, et al. The Impact of Rotavirus  
435 Vaccines on Genotype Diversity: A Comprehensive Analysis of 2 Decades of  
436 Australian Surveillance Data. *J Infect Dis* [Internet]. 2018 Jul 13 [cited 2022  
437 Aug 2];218(4):546-54. Available from:  
438 <https://pubmed.ncbi.nlm.nih.gov/29790933/>
- 439 11. Thanh HD, Tran VT, Lim I, Kim W. Emergence of Human G2P[4] Rotaviruses  
440 in the Post-vaccination Era in South Korea: Footprints of Multiple Interspecies  
441 Re-assortment Events. *Scientific Reports* 2018 8:1 [Internet]. 2018 Apr 16  
442 [cited 2022 May 26];8(1):1-10. Available from:  
443 <https://www.nature.com/articles/s41598-018-24511-y>

- 444 12. Zeller M, Rahman M, Heylen E, et al. Rotavirus incidence and genotype  
445 distribution before and after national rotavirus vaccine introduction in Belgium.  
446 Vaccine [Internet]. 2010 Nov 3 [cited 2022 Aug 2];28(47):7507–13. Available  
447 from: <https://pubmed.ncbi.nlm.nih.gov/20851085/>
- 448 13. Khandoker N, Thongprachum A, Takanashi S, et al. Molecular epidemiology of  
449 rotavirus gastroenteritis in Japan during 2014-2015: Characterization of re-  
450 emerging G2P[4] after rotavirus vaccine introduction. J Med Virol [Internet].  
451 2018 Jun 1 [cited 2022 Aug 2];90(6):1040–6. Available from:  
452 <https://pubmed.ncbi.nlm.nih.gov/29488230/>
- 453 14. Carvalho-Costa FA, de Assis RMS, Fialho AM, et al. The evolving  
454 epidemiology of rotavirus A infection in Brazil a decade after the introduction  
455 of universal vaccination with Rotarix®. BMC Pediatr [Internet]. 2019 Jan 31  
456 [cited 2022 Aug 2];19(1):1–10. Available from:  
457 <https://bmcpediatr.biomedcentral.com/articles/10.1186/s12887-019-1415-9>
- 458 15. Degiuseppe JI, Stupka JA. First assessment of all-cause acute diarrhoea and  
459 rotavirus-confirmed cases following massive vaccination in Argentina.  
460 Epidemiol Infect [Internet]. 2018 Nov 1 [cited 2022 Aug 2];146(15):1948.  
461 Available from: [/pmc/articles/PMC6452988/](https://pubmed.ncbi.nlm.nih.gov/3122988/)
- 462 16. Simwaka JC, Mpabalwani EM, Seheri M, et al. Diversity of rotavirus strains  
463 circulating in children under five years of age who presented with acute  
464 gastroenteritis before and after rotavirus vaccine introduction, University  
465 Teaching Hospital, Lusaka, Zambia, 2008-2015. Vaccine [Internet]. 2018 Nov  
466 12 [cited 2022 Aug 2];36(47):7243–7. Available from:  
467 <https://pubmed.ncbi.nlm.nih.gov/29907481/>
- 468 17. Al-Ayed MSZ, Asaad AM, Qureshi MA, Hawan AA. Epidemiology of group A  
469 rotavirus infection after the introduction of monovalent vaccine in the National  
470 Immunization Program of Saudi Arabia. J Med Virol [Internet]. 2017 Mar 1  
471 [cited 2022 Aug 2];89(3):429–34. Available from:  
472 <https://pubmed.ncbi.nlm.nih.gov/27531633/>
- 473 18. Than VT, Jeong S, Kim W. A systematic review of genetic diversity of human  
474 rotavirus circulating in South Korea. Infect Genet Evol [Internet]. 2014 Dec  
475 [cited 2018 Mar 16];28:462–9. Available from:  
476 <http://linkinghub.elsevier.com/retrieve/pii/S1567134814003086>
- 477 19. Ghosh S, Kobayashi N. Whole-genomic analysis of rotavirus strains: Current  
478 status and future prospects [Internet]. Vol. 6, Future Microbiology. Future  
479 Medicine Ltd London, UK ; 2011 [cited 2020 Oct 26]. p. 1049–65. Available  
480 from: [www.futuremedicine.com](http://www.futuremedicine.com)
- 481 20. Matthijssens J, Ciarlet M, Rahman M, et al. Recommendations for the  
482 classification of group A rotaviruses using all 11 genomic RNA segments. Arch  
483 Virol [Internet]. 2008 [cited 2018 Jan 5];153(8):1621–9. Available from:  
484 <http://link.springer.com/10.1007/s00705-008-0155-1>
- 485 21. Doan YH, Nakagomi T, Agbemabiese CA, Nakagomi O. Changes in the  
486 distribution of lineage constellations of G2P[4] Rotavirus A strains detected in  
487 Japan over 32years (1980-2011). Infection, Genetics and Evolution [Internet].  
488 2015 Aug 1 [cited 2020 Oct 27];34:423–33. Available from:  
489 <https://pubmed.ncbi.nlm.nih.gov/26026594/>
- 490 22. Agbemabiese CA, Nakagomi T, Doan YH, Do LP, Damanka S, Armah GE,  
491 Nakagomi O. Genomic constellation and evolution of Ghanaian G2P[4]  
492 rotavirus strains from a global perspective. Infection, Genetics and Evolution.  
493 2016 Nov 1;45:122–31.

- 494 23. Giammanco GM, Bonura F, Zeller M, et al. Evolution of DS-1-like human  
495 G2P[4] rotaviruses assessed by complete genome analyses. *Journal of General*  
496 *Virology* [Internet]. 2014 Jan 1 [cited 2020 Oct 27];95(PART 1):91–109.  
497 Available from:  
498 <https://www.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.05678>  
499 8-0
- 500 24. Mwangi PN, Page NA, Seheri ML, et al. Evolutionary changes between pre-  
501 and post-vaccine South African group A G2P[4] rotavirus strains, 2003–2017.  
502 *Microb Genom* [Internet]. 2022 Apr 21 [cited 2022 May 26];8(4):000809.  
503 Available from:  
504 <https://www.microbiologyresearch.org/content/journal/mgen/10.1099/mgen.0.0>  
505 00809
- 506 25. Donato CM, Pingault N, Demosthenous E, Roczo-farkas S, Bines JE.  
507 Characterisation of a G2P[4] Rotavirus Outbreak in Western Australia,  
508 Predominantly Impacting Aboriginal Children. *Pathogens* 2021, Vol 10, Page  
509 350 [Internet]. 2021 Mar 16 [cited 2022 May 26];10(3):350. Available from:  
510 <https://www.mdpi.com/2076-0817/10/3/350/htm>
- 511 26. Donato CM, Zhang ZA, Donker NC, Kirkwood CD. Characterization of G2P[4]  
512 rotavirus strains associated with increased detection in Australian states using  
513 the RotaTeq® vaccine during the 2010-2011 surveillance period. *Infect Genet*  
514 *Evol* [Internet]. 2014 Dec 1 [cited 2018 Mar 16];28:398–412. Available from:  
515 <http://linkinghub.elsevier.com/retrieve/pii/S1567134814001890>
- 516 27. Aida S, Nahar S, Paul SK, et al. Whole genomic analysis of G2P[4] human  
517 Rotaviruses in Mymensingh, north-central Bangladesh. *Heliyon*. 2016 Sep  
518 1;2(9):e00168.
- 519 28. Gómez MM, Carvalho-Costa FA, Volotão E de M, et al. Prevalence and  
520 genomic characterization of G2P[4] group A rotavirus strains during  
521 monovalent vaccine introduction in Brazil. *Infect Genet Evol* [Internet]. 2014  
522 Dec [cited 2018 Mar 16];28:486–94. Available from:  
523 <http://linkinghub.elsevier.com/retrieve/pii/S1567134814003402>
- 524 29. Scott JAG, Bauni E, Moisi JC, et al. Profile: The Kilifi Health and Demographic  
525 Surveillance System (KHDSS). *Int J Epidemiol* [Internet]. 2012 Jun [cited 2022  
526 Aug 3];41(3):650–7. Available from:  
527 <https://pubmed.ncbi.nlm.nih.gov/22544844/>
- 528 30. Otieno GP, Bottomley C, Khagayi S, et al. Impact of the introduction of  
529 rotavirus vaccine on hospital admissions for diarrhea among children in Kenya:  
530 A controlled interrupted time-series analysis. *Clinical Infectious Diseases*. 2020  
531 Jun 1;70(11):2306–13.
- 532 31. Pickett BE, Sadat EL, Zhang Y, et al. ViPR: an open bioinformatics database  
533 and analysis resource for virology research. *Nucleic Acids Res* [Internet]. 2012  
534 Jan [cited 2021 Oct 27];40(Database issue):D593. Available from:  
535 </pmc/articles/PMC3245011/>
- 536 32. Phan MVT, Anh PH, Cuong N van, et al. Unbiased whole-genome deep  
537 sequencing of human and porcine stool samples reveals circulation of multiple  
538 groups of rotaviruses and a putative zoonotic infection. *Virus Evol* [Internet].  
539 2016 Jul [cited 2018 Mar 16];2(2):vew027. Available from:  
540 <https://academic.oup.com/ve/article-lookup/doi/10.1093/ve/vew027>
- 541 33. Fujii Y, Shimoike T, Takagi H, Murakami K, Todaka-Takai R, Park Y,  
542 Katayama K. Amplification of all 11 RNA segments of group A rotaviruses




- 543 based on reverse transcription polymerase chain reaction. *Microbiol Immunol.*  
544 2012 Sep;56(9):630–8.
- 545 34. Magagula NB, Esona MD, Nyaga MM, et al. Whole Genome Analyses of  
546 G1P[8] Rotavirus Strains From Vaccinated and Non-Vaccinated South African  
547 Children Presenting With Diarrhea HHS Public Access. *J Med Virol.*  
548 2015;87(1):79–101.
- 549 35. Boom R, Sol CJ, Salimans MM, Jansen CL, Dillen PMW, Noordaa J van der.  
550 Rapid and simple method for purification of nucleic acids. *J Clin Microbiol*  
551 [Internet]. 1990 [cited 2021 Oct 27];28(3):495. Available from:  
552 /pmc/articles/PMC269651/?report=abstract
- 553 36. Endoh D, Mizutani T, Kirisawa R, et al. Species-independent detection of RNA  
554 virus by representational difference analysis using non-ribosomal  
555 hexanucleotides for reverse transcription. *Nucleic Acids Res* [Internet]. 2005  
556 [cited 2022 Aug 3];33(6):e65. Available from: /pmc/articles/PMC1074749/
- 557 37. Liu J, Gratz J, Amour C, et al. Optimization of quantitative PCR methods for  
558 enteropathogen detection. *PLoS One.* 2016 Jun 1;11(6).
- 559 38. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina  
560 sequence data. *Bioinformatics* [Internet]. 2014 Aug 1 [cited 2021 Oct  
561 27];30(15):2114. Available from: /pmc/articles/PMC4103590/
- 562 39. Bankevich A, Nurk S, Antipov D, et al. SPAdes: A New Genome Assembly  
563 Algorithm and Its Applications to Single-Cell Sequencing. *Journal of*  
564 *Computational Biology* [Internet]. 2012 May 1 [cited 2018 Jan 5];19(5).  
565 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22506599>
- 566 40. USEARCH algorithm [Internet]. [cited 2022 Sep 28]. Available from:  
567 [https://www.drive5.com/usearch/manual/usearch\\_algo.html](https://www.drive5.com/usearch/manual/usearch_algo.html)
- 568 41. Cotten M, Oude Munnink B, Canuti M, Deijs M, Watson SJ, Kellam P, van der  
569 Hoek L. Full Genome Virus Detection in Fecal Samples Using Sensitive  
570 Nucleic Acid Preparation, Deep Sequencing, and a Novel Iterative Sequence  
571 Classification Algorithm. *PLoS One* [Internet]. 2014 Apr 2 [cited 2022 Sep  
572 28];9(4):e93269. Available from:  
573 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0093269>
- 574 42. Sequencher DNA Sequence Analysis Software from Gene Codes Corporation  
575 [Internet]. [cited 2022 Sep 28]. Available from: <http://www.genecodes.com/>
- 576 43. Gurevich A, Saveliev V, Vyahhi N, Tesler G. QUASt: quality assessment tool  
577 for genome assemblies. *Bioinformatics* [Internet]. 2013 Apr 15 [cited 2021 Oct  
578 27];29(8):1072. Available from: /pmc/articles/PMC3624806/
- 579 44. Carver T, Harris SR, Berriman M, Parkhill J, McQuillan JA. Artemis: an  
580 integrated platform for visualization and analysis of high-throughput sequence-  
581 based experimental data. *Bioinformatics* [Internet]. 2012 Feb [cited 2021 Oct  
582 27];28(4):464. Available from: /pmc/articles/PMC3278759/
- 583 45. Katoh K, Misawa K, Kuma K, Miyata T. MAFFT: a novel method for rapid  
584 multiple sequence alignment based on fast Fourier transform. *Nucleic Acids Res*  
585 [Internet]. 2002 Jul 15 [cited 2021 Oct 28];30(14):3059. Available from:  
586 /pmc/articles/PMC135756/
- 587 46. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von  
588 Haeseler A, Lanfear R. IQ-TREE 2: New Models and Efficient Methods for  
589 Phylogenetic Inference in the Genomic Era. *Mol Biol Evol* [Internet]. 2020 May  
590 1 [cited 2021 Oct 28];37(5):1530–4. Available from:  
591 <https://academic.oup.com/mbe/article/37/5/1530/5721363>

- 592 47. Subha K, Minh BQ, Wong TKF, von Haeseler A, Jermin LS. ModelFinder:  
593 Fast model selection for accurate phylogenetic estimates. *Nat Methods*. 2017  
594 May 30;14(6):587–9.
- 595 48. Hoang DT, Chernomor O, Haeseler A von, Minh BQ, Vinh LS. UFBoot2:  
596 Improving the Ultrafast Bootstrap Approximation. *Mol Biol Evol* [Internet].  
597 2018 Feb 1 [cited 2021 Oct 28];35(2):518. Available from:  
598 /pmc/articles/PMC5850222/
- 599 49. Statistical software for data science | Stata [Internet]. [cited 2022 Oct 13].  
600 Available from: <https://www.stata.com/>
- 601 50. Liu L. *Fields Virology*, 6th Edition. *Clinical Infectious Diseases* [Internet]. 2014  
602 Aug 15 [cited 2022 Sep 15];59(4):613–613. Available from:  
603 <https://academic.oup.com/cid/article/59/4/613/2895607>
- 604 51. Aoki ST, Settembre EC, Trask SD, Greenberg HB, Harrison SC, Dormitzer PR.  
605 Structure of rotavirus outer-layer protein VP7 bound with a neutralizing Fab.  
606 *Science* [Internet]. 2009 Jun 6 [cited 2022 Aug 11];324(5933):1444. Available  
607 from: /pmc/articles/PMC2995306/
- 608 52. Dormitzer PR, Sun ZYJ, Wagner G, Harrison SC. The rhesus rotavirus VP4  
609 sialic acid binding domain has a galectin fold with a novel carbohydrate binding  
610 site. *EMBO Journal*. 2002 Mar 1;21(5):885–97.
- 611 53. Dennis AF, McDonald SM, Payne DC, et al. Molecular epidemiology of  
612 contemporary G2P[4] human rotaviruses cocirculating in a single U.S.  
613 community: footprints of a globally transitioning genotype. *J Virol* [Internet].  
614 2014 Apr 1 [cited 2018 Mar 15];88(7):3789–801. Available from:  
615 <http://jvi.asm.org/cgi/doi/10.1128/JVI.03516-13>
- 616 54. Rasebotsa S, Mwangi PN, Mogotsi MT, et al. Whole genome and in-silico  
617 analyses of G1P[8] rotavirus strains from pre- and post-vaccination periods in  
618 Rwanda. *Scientific Reports* 2020 10:1 [Internet]. 2020 Aug 10 [cited 2022 Aug  
619 15];10(1):1–22. Available from: <https://www.nature.com/articles/s41598-020-69973-1>
- 620 55. Zeller M, Donato C, Trovão NS, et al. Genome-Wide Evolutionary Analyses of  
621 G1P[8] Strains Isolated Before and After Rotavirus Vaccine Introduction.  
622 *Genome Biol Evol* [Internet]. 2015 Sep 1 [cited 2022 Aug 15];7(9):2473–83.  
623 Available from: <https://pubmed.ncbi.nlm.nih.gov/26254487/>
- 624 56. Munlela B, João ED, Donato CM, et al. Whole Genome Characterization and  
625 Evolutionary Analysis of G1P[8] Rotavirus A Strains during the Pre- and Post-  
626 Vaccine Periods in Mozambique (2012–2017). *Pathogens* [Internet]. 2020 Dec 1  
627 [cited 2022 Aug 19];9(12):1–19. Available from: /pmc/articles/PMC7762294/
- 628 57. Dyal-Smith ML, Lazdins I, Tregear GW, Holmes IH. Location of the major  
629 antigenic sites involved in rotavirus serotype-specific neutralization. *Proc Natl  
630 Acad Sci U S A* [Internet]. 1986 [cited 2022 Jun 3];83(10):3465–8. Available  
631 from: <https://pubmed.ncbi.nlm.nih.gov/2422651/>
- 632 58. Morozova O v., Sashina TA, Fomina SG, Novikova NA. Comparative  
633 characteristics of the VP7 and VP4 antigenic epitopes of the rotaviruses  
634 circulating in Russia (Nizhny Novgorod) and the Rotarix and RotaTeq vaccines.  
635 *Arch Virol*. 2015 Jul 15;160(7):1693–703.
- 636 59. Wei J, Li J, Zhang X, Tang Y, Wang J, Wu Y. A naturally processed epitope on  
637 rotavirus VP7 glycoprotein recognized by HLA-A2.1-restricted cytotoxic CD8+  
638 T cells. *Viral Immunol*. 2009 Jun 1;22(3):189–94.
- 639 60. Monnier N, Higo-Moriguchi K, Sun Z-YJ, Prasad BVV, Taniguchi K,  
640 Dormitzer PR. High-Resolution Molecular and Antigen Structure of the VP8\*  
641

642 Core of a Sialic Acid-Independent Human Rotavirus Strain. J Virol [Internet].  
643 2006 Feb [cited 2022 Aug 17];80(3):1513. Available from:  
644 /pmc/articles/PMC1346936/  
645  
646  
647

648



649

650


651

652

653

654 the G and P genotypes was by partial segment sequencing using the Sanger approach [1].


655



656

657

658 Fig. 2: Phylogenetic reconstruction of the 63 Kilifi G2P[4] sequences against a backdrop of  
659 350 global sequences for the VP7 and VP4 RVA genome segments using maximum  
660 likelihood (ML) methods. The Kilifi sequences are colored by the period of sample collection  
661 (either before or after vaccine introduction in Kenya). For all the global sequences, more than  
662 80% of the coding sequence (CDS) region was considered for analysis. For the Kilifi  
663 sequences, >80% CDS were used for the VP7 and 68% for the VP4 segment. The study  
664 sequences classified to the lineages indicated in each phylogenetic tree.



665


666

667 Fig. 3: Temporal pattern of the G2 and P[4] lineages observed in Kilifi and globally. (A)

668 Temporal pattern of the Kilifi G2 lineages from 2012 to 2018 and temporal pattern of the

669 global G2 lineages from 2010 to 2018. (C) Temporal pattern of the Kilifi P[4] lineages from

670 2012 to 2018 and temporal pattern of the global P[4] lineages from 2010 to 2018.



671

672

673 Fig. 4: A sequence logo showing the amino changes observed in known antigenic epitopes of  
674 G2 and P[4] proteins in the Kilifi G2P[4] relative to the ancestral DS-1 strain. The changes in  
675 amino acids are shown in different color schemes.

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693 Supplementary Figure Legend

694 Fig. S1: Phylogenetic reconstruction of the 63 Kilifi G2P[4] sequences against a backdrop of  
695 350 global sequences for the VP6, VP1, VP2, VP3, NSP1, NSP2, NSP3, NSP4, and NSP5  
696 RVA genome segments using maximum likelihood (ML) methods. The Kilifi sequences are  
697 colored by the period of sample collection (either before or after vaccine introduction in  
698 Kenya). For the Kilifi and all the global sequences, more than 80% of the coding sequence  
699 (CDS) region was considered for analysis. The study sequences classified to the lineages  
700 indicated in each phylogenetic tree.



Table 1: Baseline demographic characteristics of the children that were rotavirus positive and those found to be G2P[4] infected during the study period (2012 to 2018)

Characteristics	RVA Positives (%)	Successfully Sequenced G2P[4] (%)	All G2P[4] (%)	non-G2P [4] (%)	All G2P[4] vs non-G2P[4] P-value
Total cases	429	63 (14.7)	87 (20.3)	342 (79.7)	
Vaccine period					0.039
Pre-vaccine	215 (49.9)	33 (52.4)	35 (40.2)	180 (52.6)	
Post-vaccine	214 (50.1)	30 (47.6)	52 (59.8)	162 (47.4)	
Age (in months)					0.944
Mean (SD)	14.9 (13.1)	17.6 (16.4)	16.9 (15.4)	14.4 (12.4)	
Median (IQR)	11.7 (8.3-17.9)	11.2 (8.6-20.7)	10.6 (8.4-19.7)	12.2 (8.3-16.8)	
Age group (in months)					0.092
0-11m	216 (50.4)	33 (52.4)	47 (54.0)	216 (50.4)	
12– 23m	169 (39.4)	20 (31.2)	26 (29.9)	143 (41.8)	
24– 59m	35 (8.2)	7 (11.1)	11 (12.6)	24 (7.0)	
>=60 m	9 (2.1)	3 (4.8)	3 (3.5)	6 (1.7)	
Gender					0.789
Male	251 (51.5)	37 (58.7)	52 (59.7)	199 (58.2)	
Vaccination status					0.129
Vaccinated	88 (20.6)	14 (22.2)	22 (25.6)	66 (19.4)	
Not vaccinated	215 (50.4)	33 (52.4)	35 (40.7)	180 (52.8)	
Unknown	124 (29.0)	16 (25.4)	29 (33.7)	95 (27.9)	
<sup>1</sup> Full vaccination	79 (18.4)	13 (20.6)	21 (24.1)	58 (17.0)	0.256

<sup>1</sup> Full vaccination implies that the participants received two doses of the Rotarix vaccine as recommended by WHO

Table 2: Percentage nucleotide and amino acid identity for the Kilifi G2P[4] strains

Genome segment	Percentage nucleotide similarity	Percentage amino acid similarity
VP4	94.3-100	96.8-100
VP7	94.3-100	96.3-100
VP6	94.0-100	96.0-100
VP1	93.9-100	98.0-100
VP2	97.2-100	99.2-100
VP3	87.1-100	92.1-100
NSP1	95.7-100	96.0-100
NSP2	97.3-100	97.5-100
NSP3	97.1-100	98.4-100
NSP4	85.0-100	91.5-100
NSP5	94.5-100	94.5-100